Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints
Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding ...
Fintel on MSN7h
Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation
Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...
Silence Therapeutics initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your ...
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges
Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...
Analysts Set Silence Therapeutics plc (NASDAQ:SLN) PT at $54.75
Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...
Investing8d
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges
Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture in its development pipeline. With promising assets targeting ...
Nasdaq8d
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides ...